Harald Weigmann

1.4k total citations
31 papers, 982 citations indexed

About

Harald Weigmann is a scholar working on Psychiatry and Mental health, Pharmacology and Molecular Biology. According to data from OpenAlex, Harald Weigmann has authored 31 papers receiving a total of 982 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Psychiatry and Mental health, 9 papers in Pharmacology and 6 papers in Molecular Biology. Recurrent topics in Harald Weigmann's work include Schizophrenia research and treatment (15 papers), Treatment of Major Depression (8 papers) and Epilepsy research and treatment (7 papers). Harald Weigmann is often cited by papers focused on Schizophrenia research and treatment (15 papers), Treatment of Major Depression (8 papers) and Epilepsy research and treatment (7 papers). Harald Weigmann collaborates with scholars based in Germany, United Kingdom and Switzerland. Harald Weigmann's co-authors include Christoph Hiemke, Sebastian Härtter, Hermann Wetzel, Norbert Dahmen, Armin Szegedi, Ion Anghelescu, Thomas Friedberg, Michael Arand, Franz Oesch and Ximing Wang and has published in prestigious journals such as Pharmaceutical Research, Progress in Neuro-Psychopharmacology and Biological Psychiatry and BMC Psychiatry.

In The Last Decade

Harald Weigmann

29 papers receiving 920 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Harald Weigmann Germany 20 547 287 187 167 120 31 982
Gabriel Eckermann Germany 9 385 0.7× 213 0.7× 123 0.7× 94 0.6× 111 0.9× 24 766
Lawrence J. Albers United States 16 286 0.5× 162 0.6× 181 1.0× 199 1.2× 150 1.3× 26 781
Barry D. Zussman United Kingdom 15 253 0.5× 344 1.2× 218 1.2× 138 0.8× 152 1.3× 20 915
Tadashi Ohkubo Japan 22 341 0.6× 500 1.7× 274 1.5× 297 1.8× 244 2.0× 69 1.3k
R. E. Haddock United Kingdom 8 278 0.5× 431 1.5× 368 2.0× 147 0.9× 109 0.9× 12 954
Edgar P. Spencer United Kingdom 17 813 1.5× 435 1.5× 95 0.5× 325 1.9× 133 1.1× 25 1.6k
M. Amey Switzerland 14 304 0.6× 398 1.4× 204 1.1× 149 0.9× 69 0.6× 16 799
I. Gaertner Germany 12 320 0.6× 171 0.6× 149 0.8× 156 0.9× 110 0.9× 13 715
K. Fredricson Overø Denmark 18 561 1.0× 611 2.1× 322 1.7× 282 1.7× 158 1.3× 39 1.4k
Manickam Aravagiri United States 23 1.0k 1.9× 272 0.9× 158 0.8× 376 2.3× 359 3.0× 50 1.8k

Countries citing papers authored by Harald Weigmann

Since Specialization
Citations

This map shows the geographic impact of Harald Weigmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harald Weigmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harald Weigmann more than expected).

Fields of papers citing papers by Harald Weigmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harald Weigmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harald Weigmann. The network helps show where Harald Weigmann may publish in the future.

Co-authorship network of co-authors of Harald Weigmann

This figure shows the co-authorship network connecting the top 25 collaborators of Harald Weigmann. A scholar is included among the top collaborators of Harald Weigmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harald Weigmann. Harald Weigmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Weigmann, Harald, et al.. (2025). Real-world effects of hyoscine butylbromide combined with paracetamol in women with dysmenorrhea: a patient survey. Frontiers in Medicine. 12. 1581059–1581059.
2.
3.
Weiser, Thomas & Harald Weigmann. (2019). Effect of Caffeine on the Bioavailability and Pharmacokinetics of an Acetylsalicylic Acid-Paracetamol Combination: Results of a Phase I Study. Advances in Therapy. 36(3). 597–607. 17 indexed citations
4.
Schneider, Edith, Michael Linden, Harald Weigmann, et al.. (2011). Early reduction in painful physical symptoms is associated with improvements in long-term depression outcomes in patients treated with duloxetine. BMC Psychiatry. 11(1). 150–150. 22 indexed citations
5.
Kornhuber, Johannes, Harald Weigmann, J. Röhrich, et al.. (2005). Region specific distribution of levomepromazine in the human brain. Journal of Neural Transmission. 113(3). 387–397. 15 indexed citations
6.
Schneider, Bernhard, Harald Weigmann, Christoph Hiemke, Bernhard Weber, & J. Fritze. (2004). Reduction Of Clozapine-Induced Hypersalivation By Pirenzepine Is Safe. Pharmacopsychiatry. 37(2). 43–45. 24 indexed citations
7.
Müller, Matthias J., Aleksandra Dragičević, I. Gaertner, et al.. (2003). Therapeutic Drug Monitoring of Tricyclic Antidepressants: How Does it Work under Clinical Conditions?. Pharmacopsychiatry. 36(3). 98–104. 45 indexed citations
8.
Hiemke, Christoph, A. Peled, Jack Hadjez, et al.. (2002). Fluvoxamine Augmentation of Olanzapine in Chronic Schizophrenia: Pharmacokinetic Interactions and Clinical Effects. Journal of Clinical Psychopharmacology. 22(5). 502–506. 51 indexed citations
9.
Härtter, Sebastian, Gunnel Tybring, Thomas Friedberg, Harald Weigmann, & Christoph Hiemke. (2002). The N-Demethylation of the Doxepin Isomers Is Mainly Catalyzed by the Polymorphic CYP2C19. Pharmaceutical Research. 19(7). 1034–1037. 23 indexed citations
10.
Weigmann, Harald, et al.. (2001). Fluvoxamine But Not Sertraline Inhibits the Metabolism of Olanzapine: Evidence From A Therapeutic Drug Monitoring Service. Therapeutic Drug Monitoring. 23(4). 410–413. 56 indexed citations
11.
Weigmann, Harald, et al.. (2001). Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography. Journal of Chromatography B Biomedical Sciences and Applications. 759(1). 63–71. 56 indexed citations
12.
Weigmann, Harald, Sebastian Härtter, Metin Bagli, & Christoph Hiemke. (2000). Steady state concentrations of clomipramine and its major metabolite desmethylclomipramine in rat brain and serum after oral administration of clomipramine. European Neuropsychopharmacology. 10(5). 401–405. 31 indexed citations
13.
Härtter, Sebastian, Harald Weigmann, & Christoph Hiemke. (2000). Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection. Journal of Chromatography B Biomedical Sciences and Applications. 740(1). 135–140. 30 indexed citations
14.
Lammers, C., Michael Deuschle, Harald Weigmann, et al.. (1999). Coadministration of Clozapine and Fluvoxamine in Psychotic Patients - Clinical Experience. Pharmacopsychiatry. 32(2). 76–77. 27 indexed citations
15.
Szegedi, Armin, Ion‐George Anghelescu, S. Schlegel, et al.. (1999). Addition of Low-Dose Fluvoxamine to Low-Dose Clozapine Monotherapy in Schizophrenia: Drug Monitoring and Tolerability Data from a Prospective Clinical Trial. Pharmacopsychiatry. 32(4). 148–153. 53 indexed citations
16.
Schmitt, Ulrich, Norbert Dahmen, Harald Weigmann, et al.. (1999). Chronic Oral Haloperidol and Clozapine in Rats: A Behavioral Evaluation. Neuropsychobiology. 39(2). 86–91. 24 indexed citations
17.
Ulrich, S., et al.. (1999). Fishing for a drug: solid-phase microextraction for the assay of clozapine in human plasma. Journal of Chromatography B Biomedical Sciences and Applications. 731(2). 231–240. 28 indexed citations
18.
Anghelescu, Ion, Armin Szegedi, S. Schlegel, et al.. (1998). Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial. European Neuropsychopharmacology. 8(4). 315–320. 8 indexed citations
19.
Schmitt, Ulrich, Harald Weigmann, Boris von Keller, et al.. (1998). Chronical haloperidol and clozapine treatment in rats: Differential RNA display analysis, behavioral studies and serum level determination. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 22(7). 1129–1139. 10 indexed citations
20.
Wetzel, Hermann, Ion Anghelescu, Armin Szegedi, et al.. (1998). Pharmacokinetic Interactions of Clozapine With Selective Serotonin Reuptake Inhibitors. Journal of Clinical Psychopharmacology. 18(1). 2–9. 104 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gabriel Eckermann Breakdown of academic impact, for papers by Lawrence J. Albers Breakdown of academic impact, for papers by Barry D. Zussman Breakdown of academic impact, for papers by Tadashi Ohkubo Breakdown of academic impact, for papers by R. E. Haddock Breakdown of academic impact, for papers by Edgar P. Spencer Breakdown of academic impact, for papers by M. Amey Breakdown of academic impact, for papers by I. Gaertner Breakdown of academic impact, for papers by K. Fredricson Overø Breakdown of academic impact, for papers by Manickam Aravagiri
Rankless by CCL
2026